GlassScriptPhysician profile
Larissa C Smith
NPI 1033451687
$8,154.28
in general payments reported to CMS, 2019-2025
30 companies · $6,121 in 2025
The $6,121 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.16 · 2020: $33.78 · 2021: $422 · 2022: $372 · 2023: $477 · 2024: $662 · 2025: $6,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Food and Beverage: $1,835 · Travel and Lodging: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Food and Beverage | $1,834.56 |
| Travel and Lodging | $926.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,001.30 | 2020-2025 | |
| Astellas Pharma US INC | $375.22 | 2023-2025 | Veozah |
| Abbvie INC. | $255.75 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Daiichi Sankyo INC. | $214.05 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $191.45 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.79 | 2021-2025 | |
| Exeltis, USA INC. | $111.84 | 2021-2024 | Tyblume |
| Agile Therapeutics, INC. | $111.78 | 2023-2024 | Twirla |
| Millicent US INC | $103.41 | 2023-2025 | Femlyv, Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $84.96 | 2023-2024 | Myfembree |
| Pfizer INC. | $66.93 | 2024-2025 | |
| Minerva Surgical, INC | $48.34 | 2024 | |
| Sage Therapeutics, LLC | $45.87 | 2021-2025 | Zurzuvae |
| Meditrina | $36.25 | 2023-2025 | |
| Therapeuticsmd, INC. | $32.85 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $30.94 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $30.18 | 2023 | Seglentis |
| Hologic Sales and Service, LLC | $29.17 | 2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Dexcom, INC. | $23.49 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $21.57 | 2025 | Jada System |
| Genmab U.S., INC. | $21.16 | 2023 | Tivdak |
| Exact Sciences Corporation | $19.61 | 2023 | Cologuard Collection Kit |
| Innovation Technologies INC | $19.60 | 2022 | |
| Mission Pharmacal Company | $19.15 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.40 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $15.99 | 2021 | |
| Amgen INC. | $14.55 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.78 | 2019 | |
| Coopersurgical, INC. | $12.60 | 2019 | |
| Merck Sharp & Dohme LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.